-
Mashup Score: 30Novartis' Scemblix leaps into newly diagnosed leukemia—where winning over doctors may take time - 8 day(s) ago
Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. | Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. The drug will face a couple of challenges as Novartis works to reach more patients in the setting.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3ICER raises cost-effective price for Pfizer's ATTR drug in final analysis but still calls for hefty discount - 17 day(s) ago
After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S. | After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S. drug cost watchdog has provided a final analysis that includes a smaller—yet still hefty—price reduction demand.
Source: www.fiercepharma.comCategories: General Medicine News, CardiologistsTweet-
To meet the cost-effectiveness bar of between $100,000 and $150,000 per QALY tafamidis and TTR-stabilizing agent class should cost $13,600 to 39,000 a year ICER raises cost-effective price for Pfizer's ATTR drug in final analysis, calls for hefty discount https://t.co/1IZtnWizOq
-
-
Mashup Score: 0Leqembi's vial design could result in hundreds of millions in annual Medicare waste: study - 23 day(s) ago
As payers tally up the potential costs of anti-amyloid antibodies for Alzheimer’s disease, a new study suggests that the vial design for Eisai and Biogen’s Leqembi could result in hundreds of milli | As payers tally up the potential costs of anti-amyloid antibodies for Alzheimer’s disease, a new study suggests that the vial design for Eisai and Biogen’s Leqembi could result in hundreds of millions of dollars in wasted spending each year for Medicare.
Source: www.fiercepharma.comCategories: General Medicine News, Future of MedicineTweet-
Leqembi's vial design could result in hundreds of millions in annual #Medicare #waste: study - Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be unused and discarded https://t.co/xu6KABDQXz
-
-
Mashup Score: 3Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche's Tecentriq - 24 day(s) ago
Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer (ES- | Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer.
Source: www.fiercepharma.comCategories: General Medicine News, Oncologists1Tweet-
RT @FiercePharma: Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche's Tecentriq https://t.co/vC6KBfMFzr
-
-
Mashup Score: 1Merck's Keytruda stages comeback in head and neck cancer with trial win in earlier-stage disease - 1 month(s) ago
Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a new positive readout can return Keytruda to glory in head and neck cancer about two years after a prior failure.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet-
RT @FiercePharma: Merck's Keytruda stages comeback in head and neck cancer with trial win in earlier-stage disease https://t.co/N6bdWTcEcK
-
-
Mashup Score: 4
BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed FDA approval. | BeiGene is pricing Tevimbra at a 10% discount to other PD-1 therapies available in second-line esophageal squamous cell carcinoma.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet-
RT @chuminhua432: $BGNE BeiGene launches PD-1 drug #Tevimbra at 10% discount to Merck's Keytruda https://t.co/5qosIJIB8e BeiGene has offici…
-
-
Mashup Score: 2
The world’s three premier makers of insulin are reducing prices like never before. | In a span of less than three weeks, Eli Lilly, Novo Nordisk and Sanofi have announced price cuts of their insulins in the U.S. Sanofi was the latest to fall in line, saying Thursday that it would slash the price of its most popular insulin, Lantus, by 78% and capping the out-of-pocket cost at $35 per month for all patients with commercial insurance.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet-
Thus, the number 3 reason insulin prices came down was voluntary action by insulin manufacturers, (answering the call to do so by patients, patient advocates, and leaders like Senator Sanders who held hearings on insulin prices and demanded action). https://t.co/LaO0Nnepuj
-
-
Mashup Score: 0
The PCMPA has slammed Moderna | The PCMPA has slammed Moderna over an unapproved WhatsApp message that offered children 1,500 pounds sterling ($2,000) to participate in a clinical trial of its COVID-19 booster vaccine.
Source: www.fiercepharma.comCategories: General Medicine News, Infectious DiseaseTweet-
“the Panel considered that this brought discredit upon and reduced confidence in the pharmaceutical industry,” https://t.co/P1fhiGzEkp
-
-
Mashup Score: 1New migraine drugs less effective than previous generation of triptan meds: BMJ study - 2 month(s) ago
A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migra | A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migraines than a previous class of medicines.
Source: www.fiercepharma.comCategories: General Medicine News, General NewsTweet-
BMJ says newer migraine drugs are less effective than Tylenol https://t.co/VetfSB4iLl
-
-
Mashup Score: 3Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI into biopharma marketing - 2 month(s) ago
No longer a far-off futuristic idea, artificial intelligence technology has seen its popularity skyrocket in recent years. | Amid all the AI hype, pharma marketers are taking a more cautious approach to implementing the technology.
Source: www.fiercepharma.comCategories: General Medicine News, Future of MedicineTweet-
Also important to retain IP - which is why @healthquant and @RingerSciences are creating custom LLMs for healthcare Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing https://t.co/kP9hYVjdX5 #pharma #feedly
-
Ascimitinib is such a scam. No sensible oncologist would give this drug over imatinib. The trial is incredibly dishonest. I'm glad this article discussed our paper on the topic, although it did not fully discuss all our arguments. https://t.co/x4TtDHpTVj https://t.co/o8f3kj0IhL